

40mm

160mm



WeKare Terbinafine Spray 1%w/v

Active Ingredient:
Terbinafine Hydrochloride 1%w/v

Product Description:
Clear colourless solution with characteristic odour.

Indication:
For the treatment of fungal skin infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), pityriasis versicolor (tinea versicolor) and cutaneous candidiasis.

Direction of Use:
Cleanse and dry the affected area thoroughly before application. Spray WeKare Terbinafine Spray 1%w/v to the affected area once a day for one week. Spray from a distance of 5cm to 10cm. The treatment should be continued for 2 weeks after the disappearance of all signs of infection to prevent recurrence. Attention to hygiene is important in the management of fungal diseases, particularly of the folds and the feet. Consult the doctor if there are no signs of improvement after 4 weeks.

Route of Administration: Topical

Pharmacodynamics:
Terbinafine is an allylamine which has a broad spectrum of antifungal activity in fungal infections of the skin. It's action being fungicidal against dermatophytes, moulds and certain dimorphic fungi. It has a fungicidal or fungistatic action on yeasts depending on the species involved. Terbinafine interferes with fungal ergosterol biosynthesis at an early stage. This leads to a deficiency in ergosterol and to intracellular accumulation of squalene, resulting in fungal cell death.

Terbinafine acts by inhibiting squalene epoxidase in the fungal cell membrane. The squalene epoxidase is not dependent on the cytochrome P450 system. Terbinafine does not have any influence on the metabolism of hormones or of other medicines.

Pharmacokinetics:
Less than 5% of the dose is absorbed after topical application in humans; systemic exposure is thus very slight. Biotransformation results in metabolites with no antifungal activity, which is excreted predominantly in the urine and the faeces. The elimination half-life is 17 hours. There is no evidence of accumulation. At the level of the stratum corneum, fungicidal concentrations of terbinafine can be measured up to 7 days after the last administration.

Contraindications:
Contraindicated in patients with known hypersensitivity to any of the ingredients in the product.

Warnings and Precautions:
For external use only. Avoid contact or use the medication in the eyes, nose, or mouth, or inside the vagina. If you do get the medication in those areas, flush with plenty of water. Not to be taken orally.

WeKare Terbinafine Spray 1%w/v Semburan Terbinafine 1%w/v WeKare WeKare Terbinafine 喷雾剂 1%w/v

Bahan Aktif:
Terbinafine Hydrochloride 1%w/v

Deskripsi:
Larutan tanpa berwarna yang berbau khas.

Indikasi:
Untuk rawatan jangkitan kulit pada kulit seperti kaki atlet (tinea pedis), gatal pangkal paha (tinea cruris), kurap (tinea corporis), panau (tinea versicolor) dan kandidiasis kulit.

Cara Penggunaan:
Bersihkan dan keringkan kawasan yang terjangkit sebelum penggunaan. Semburkan Semburan Terbinafine 1%w/v WeKare ke kawasan yang terjangkit sekali sehari selama satu minggu. Sembur dari jarak 5 hingga 10 cm. Rawatan perlu diteruskan selama 2 minggu selepas semua tanda jangkitan hilang bagi mengelakkan jangkitan semula. Penjagaan kebersihan diri amat penting dalam pengurusan jangkitan kulit, terutamanya pada bahagian lipatan kulit dan kaki. Sila rujuk kepada doktor sekiranya tiada tanda-tanda pemulihan selepas 4 minggu.

Laluan Pemberian Ubat: Topikal

Farmakodinamik:
Terbinafine ialah allylamine yang mempunyai spektrum luas aktiviti antikulat dalam jangkitan kulit pada kulit. Ia bertindak sebagai racun kulit terhadap dermatofiti, acuan dan kulat dimorf tertentu. Ia mempunyai tindakan fungicidal atau fungistatik pada yis bergantung kepada spesies yang terlibat. Terbinafine mengganggu biosintesis ergosterol kulit pada peringkat awal. Ini membawa kepada kekurangan ergosterol dan pengumpulan squalene intraselular, mengakibatkan kematian sel kulit.

Terbinafine bertindak dengan menghalang squalene epoxidase dalam membran sel kulit. Squalene epoxidase tidak bergantung pada sistem cytochrome P450. Terbinafine tidak mempunyai sebarang pengaruh ke atas metabolisme hormon atau ubat-ubatan lain.

Farmakokinetik:
Kurang daripada 5% daripada dos diserap selepas penggunaan topikal pada manusia; Oleh itu, pencedahan sistemik adalah sangat sedikit. Biotransformasi menghasilkan metabolit tanpa aktiviti antikulat, yang diekskresikan terutamanya dalam air kencing dan najis. Separuh hayat penyingkiran ialah 17 jam. Tidak ada bukti pengumpulan. Pada tahap stratum corneum, kepekatan fungicidal terbinafine boleh diukur sehingga 7 hari selepas pentadbiran terakhir.

Kontraindikasi:
Kontraindikasi pada pesakit yang diketahui hipersensitiviti kepada mana-mana bahan dalam produk.

Amaran dan Perhatian:
Untuk kegunaan luaran sahaja. Elakkan sentuhan atau penggunaan ubat ini pada mata, hidung, atau mulut, atau di dalam feses.

Active ingredient:
Terbinafine Hydrochloride 1%w/v

Appearance:
Transparent colorless liquid, with characteristic odour.

Indication:
Used for the treatment of fungal skin infections such as athlete's foot (tinea pedis), groin rash, body rash, and skin conditions like candidiasis.

Usage instructions:
Cleanse the affected area thoroughly before use. Spray WeKare Terbinafine Spray 1%w/v on the affected area once a day, maintaining a distance of 5 to 10 cm. Continue treatment for 2 weeks after the symptoms disappear. Pay attention to personal hygiene to prevent recurrence, especially in skin folds and feet. Consult a doctor if there is no improvement after 4 weeks.

Route of administration: External

Pharmacodynamics:
Terbinafine is a allylamine, which has a broad spectrum of antifungal activity in fungal infections of the skin. Its action being fungicidal against dermatophytes, moulds and certain dimorphic fungi. It has a fungicidal or fungistatic action on yeasts depending on the species involved. Terbinafine interferes with fungal ergosterol biosynthesis at an early stage. This leads to a deficiency in ergosterol and to intracellular accumulation of squalene, resulting in fungal cell death.

Terbinafine acts by inhibiting squalene epoxidase in the fungal cell membrane. The squalene epoxidase is not dependent on the cytochrome P450 system. Terbinafine does not have any influence on the metabolism of hormones or of other medicines.

Pharmacokinetics:
Less than 5% of the dose is absorbed after topical application in humans; systemic exposure is thus very slight. Biotransformation results in metabolites with no antifungal activity, which is excreted predominantly in the urine and the faeces. The elimination half-life is 17 hours. There is no evidence of accumulation. At the level of the stratum corneum, fungicidal concentrations of terbinafine can be measured up to 7 days after the last administration.

Contraindications:
Contraindicated in patients with known hypersensitivity to any of the ingredients in the product.

Warnings and Precautions:
For external use only. Avoid contact or use the medication in the eyes, nose, or mouth, or inside the vagina. If you do get the medication in those areas, flush with plenty of water. Not to be taken orally.

Front Back



WeKare Terbinafine Spray 1%w/v

If symptoms persist, please consult a doctor. Keep out of reach of children.

Effects on Ability to Drive and Use Machines:
Not known

Interactions with Other Medicaments:
Not known

Pregnancy & Lactation:
There is no clinical experience in pregnant women; therefore, unless the potential benefits outweigh any potential risks, it should not be administered during pregnancy. Terbinafine is excreted in breast milk and although the amount involved is small, mothers should not receive it whilst breastfeeding. Infants should also not be allowed to come into contact with any treated skin, including the breast.

Adverse Effects / Undesirable Effects:
Redness, itching or stinging occasionally occur at the site of application which does not necessarily require discontinuation. However, these reactions should be distinguished from allergic reactions which rarely occur but require discontinuation.

Symptoms and Treatment of Overdose:
No case of overdose has been reported so far. However, should a large amount of the preparation be inadvertently ingested, adverse effects similar to those observed with an overdose of a tablet form of terbinafine are to be expected. These include headache, nausea, vomiting, epigastric pain and dizziness.

In case of accidental oral ingestion, gastric lavage and / or symptomatic supportive treatment should be performed as soon as possible.

Dosage Form: Liquid

Packing Size: 25ml

Storage Conditions:
Store below 30°C. Protect from direct sunlight.

Shelf Life:
Please refer to the packaging. Do not use beyond the expiry date.

The information contained in this leaflet is limited. For further information, please consult your doctor or pharmacist.

Product Registration Holder:
Wen Ken Marketing Sdn Bhd
24, Jalan Lambak, Taman Johor,
81200 Johor Bahru, Johor, Malaysia.

WeKare Terbinafine Spray 1%w/v Semburan Terbinafine 1%w/v WeKare WeKare Terbinafine 喷雾剂 1%w/v

WeKare Terbinafine 1%w/v WeKare

Jika ubat terkena di kawasan tersebut, bilas dengan banyak air. Dilarang makan. Jika simptom berterusan, sila merujuk kepada doktor.

Jauhkan daripada capaian kanak-kanak.

Kesan pada Keupayaan Memandu dan Menggunakan Mesin: Tidak diketahui

Interaksi dengan Ubat Lain: Tidak diketahui

Kehamilan & Penyusuan:
Tidak ada pengalaman klinikal pada wanita hamil; oleh itu, kecuali manfaat berpotensi melebihi risiko berpotensi, ia tidak patut diberikan semasa hamil. Terbinafine diekskresikan dalam susu ibu dan walaupun kandungannya sedikit, ibu tidak patut menerimanya semasa penyusuan. Bayi juga tidak patut dibesarkan bersentuhan dengan mana-mana kulit yang dirawat, termasuk payudara.

Kesan-Kesan Sampingan:
Kemerahan, gatal-gatal atau kepedihan kadang-kadang berlaku di tapak penggunaan yang tidak semestinya memerlukan pemberhentian. Walau bagaimanapun, tindak balas ini harus dibezakan daripada tindak balas alahan yang jarang berlaku tetapi memerlukan pemberhentian.

Simptom dan Rawatan untuk Kelebihan Dos:
Tidak ada kes dos berlebihan dilaporkan selakati ini. Walau bagaimanapun, sekiranya sejumlah besar ubat termakan secara tidak sengaja, kesan buruk yang serupa dengan yang diperhatikan dengan dos berlebihan bentuk tablet terbinafine dijangkakan. Ini termasuk sakit kepala, loya, muntah, sakit epigastrik dan pening. Sekiranya tertelan secara oral secara tidak sengaja, lavage gastrik dan/atau rawatan sokongan simptomatik harus dilakukan secepat mungkin.

Dos: Cecair

Saiz pembungkusan: 25ml

Keadaan Penyimpanan:
Simpan di bawah 30°C. Lindungi daripada cahaya.

Tempoh Hayat:
Sila rujuk kepada bungkusan. Jangan guna selepas tamat tarikh luput.

Maklumat yang terkandung dalam risalah ini adalah terhad. Untuk maklumat lanjut, sila rujuk kepada doktor atau ahli farmasi anda.

在的益处超过任何潜在的风险，否则不应在怀孕期间服用。 虽然分泌量很少，但母亲在哺乳期间不应使用。 婴儿也不应接触任何处理过的皮肤，包括乳房。

副作用:
使用部位偶尔会出现发红、瘙痒或刺痛，但不一定需要停药。然而，这些反应应与很少发生但需要停止使用的过敏反应区分开来。

过量服用的症状和治疗:
过量症状和处理: 到目前为止尚未报告过任何过量服用的案例。然而，如果不慎摄入大量药物，可能会出现类似于口服特比萘芬片剂过量的不良反应。这些症状包括头痛、恶心、呕吐、上腹部疼痛和头晕等。

如果不慎误食，应尽快进行胃洗和/或进行症状支持性治疗。

剂型: 液体

包装: 25毫升

贮存:
存放于30°C以下。避免阳光直射。

有效期:
请参考包装。超过有效期请勿使用。 此说明书仅属概述，预知详情，请咨询您的医生或药剂师。

Date of Revision: JULY 2025

100mm